Prostaglandin D2 (PGD2) is a major cyclooxygenase mediator that is synthesized by activated human mast cells and other immune cells. The biological effects of PGD2 are mediated by D-prostanoid (DP1), DP2 (CRTH2) and thromboxane prostanoid (TP) receptors that are expressed on several immune and non-immune cells involved in allergic inflammation. PGD2 exerts various proinflammatory effects relevant to the pathophysiology of allergic disorders. Several selective, orally active, DP2 receptor antagonists and a small number of DP1 receptor antagonists are being developed for the treatment of allergic disorders. Areas covered: The role of DP2 and DP1 receptor antagonists in the treatment of asthma and allergic rhinitis. Expert opinion: Head-to-head studies that compare DP1 antagonists with the standard treatment for allergic rhinitis are necessary to verify the role of these novel drugs as mono- or combination therapies. Further clinical trials are necessary to verify whether DP2 antagonists as monotherapies or, more likely, as add-on therapies, will be effective for the treatment of different phenotypes of adult and childhood asthma. Long-term studies are necessary to evaluate the safety of targeted anti- PGD2 treatments.

Prostaglandin D2 receptor antagonists in allergic disorders: safety, efficacy and future perspectives / Marone, Giancarlo; Galdiero, Maria Rosaria; Pecoraro, Antonio; Pucino, Valentina; Criscuolo, Gjada; Triassi, Maria; Varricchi, Gilda. - In: EXPERT OPINION ON INVESTIGATIONAL DRUGS. - ISSN 1354-3784. - 28:1(2019), pp. 73-84. [10.1080/13543784.2019.1555237]

Prostaglandin D2 receptor antagonists in allergic disorders: safety, efficacy and future perspectives

Marone, Giancarlo;Galdiero, Maria Rosaria;Pecoraro, Antonio;Pucino, Valentina;Criscuolo, Gjada;Triassi, Maria;Varricchi, Gilda
2019

Abstract

Prostaglandin D2 (PGD2) is a major cyclooxygenase mediator that is synthesized by activated human mast cells and other immune cells. The biological effects of PGD2 are mediated by D-prostanoid (DP1), DP2 (CRTH2) and thromboxane prostanoid (TP) receptors that are expressed on several immune and non-immune cells involved in allergic inflammation. PGD2 exerts various proinflammatory effects relevant to the pathophysiology of allergic disorders. Several selective, orally active, DP2 receptor antagonists and a small number of DP1 receptor antagonists are being developed for the treatment of allergic disorders. Areas covered: The role of DP2 and DP1 receptor antagonists in the treatment of asthma and allergic rhinitis. Expert opinion: Head-to-head studies that compare DP1 antagonists with the standard treatment for allergic rhinitis are necessary to verify the role of these novel drugs as mono- or combination therapies. Further clinical trials are necessary to verify whether DP2 antagonists as monotherapies or, more likely, as add-on therapies, will be effective for the treatment of different phenotypes of adult and childhood asthma. Long-term studies are necessary to evaluate the safety of targeted anti- PGD2 treatments.
2019
Prostaglandin D2 receptor antagonists in allergic disorders: safety, efficacy and future perspectives / Marone, Giancarlo; Galdiero, Maria Rosaria; Pecoraro, Antonio; Pucino, Valentina; Criscuolo, Gjada; Triassi, Maria; Varricchi, Gilda. - In: EXPERT OPINION ON INVESTIGATIONAL DRUGS. - ISSN 1354-3784. - 28:1(2019), pp. 73-84. [10.1080/13543784.2019.1555237]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/725752
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 48
  • ???jsp.display-item.citation.isi??? 46
social impact